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Mechanism of albuminuria associated with cardiovascular dis-
ease and kidney disease. The major underlying factors associ-
ated with tissue damage and fibrosis in cardiovascular and kid-
ney disease are the up-regulation and action of growth factors
such as transforming growth factor-beta (TGF-b) and cytokines
produced in response to changes in systemic factors, particularly
blood pressure or hyperglycemia. This study identifies the rela-
tionship of elevated levels of TGF-b to increased levels of in-
tact albumin in the urine (micro- and macroalbuminuria). This
mechanism may be directly linked to the effect of TGF-b on al-
bumin uptake and the lysosomal breakdown of filtered albumin
by proximal tubular cells prior to excretion.
It is becoming apparent that the linkage between
cardiovascular disease and kidney disease is the up-
regulation and action of TGF-b stimulated by in-
creased blood pressure or hyperglycemia, or both. This
growth factor is known to induce tissue fibrosis [1, 2].
Other growth hormones and cytokines may also be up-
regulated. Recent studies would suggest that increased
levels of TGF-b will also have a profound effect on the
level of albuminuria. This mechanism involves recently
identified pathways for filtered albumin processing in the
kidney, as shown in Figure 1 [3]. Albumin destined for
excretion appears obligated to traverse the degradation
pathway. The majority of albumin (>95%) is excreted
as low-molecular-weight (<5000 daltons) peptide frag-
ments. Humans normally excrete 1 to 2 g of albumin-
derived fragments per day [4], and these fragments are
not detectable by routine immunologic-based assays used
to quantitate urinary albumin excretion.
METHODS
Renal TGF-b1 and TGF-b–inducible gene-h3 (big-h3)
mRNA expression was analyzed by real-time quantita-
tive RT-PCR (TaqMan system) for control rats, diabetic
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rats, hypertensive rats, and both diabetic and hyperten-
sive rats. Albuminuria was determined by radioactiv-
ity (measures both intact albumin and albumin-derived
fragments) and immunoassay (measures only intact im-
munoreactive albumin).
RESULTS AND DISCUSSION
Elevated levels of TGF-b have been shown to occur in
diabetic and hypertensive rats [5–6], and correlate with
decreased lysosomal activity in vivo. This was demon-
strated through its effects on the normally rapid desulfa-
tion of dextran sulfate by lysosomal sulfatases which was
reduced in the diabetic and hypertensive states [5–6].
The major finding in these studies is that the relative
change in fractional clearance or excretion rate of in-
tact immunoreactive albumin far outweighs the relative
change in total albumin fractional clearance or excretion
rate (intact albumin and albumin-derived fragments) de-
termined by radioactivity using radiolabeled albumin. In
some diseased states such as hypertension, we have ob-
served no change in the fractional clearance of total albu-
min, as determined by radioactivity, but major changes in
intact albumin clearance, as determined by immunoassay
[6].
The results can be explained by the model shown in
Figure 2. If clearance results were interpreted on the ba-
sis of immunoreactive albumin alone then it could be
thought that the changes would be due to some per-
meability defect. However, when one accounts for all
of the albumin that has been filtered and appears in
the urine, then a totally different picture emerges. In
all the disease states studied the relative change in total
albumin-derived product excretion is small; therefore,
permeability changes play only a relatively minor role.
The major issue is the balance in the pool of albumin-
derived material excreted between intact albumin and
albumin-derived fragments (i.e., intact albumin excretion
can increase 10-fold with out any changes in total albu-
min excretion). Lysosomal inhibitors such as TGF-b are
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Fig. 1. Proposed pathways for handling of fil-
tered albumin in the kidney. In normal kid-
neys, the major proportion of filtered albu-
min is retrieved and returned to the blood
supply intact. A relatively smaller proportion
(<5%) is directed toward the lysosome, de-
graded to small peptide fragments (molecu-
lar weight <5000 daltons), exocytosed to the
tubular lumen, and excreted in the urine [3].
These albumin-derived fragments are not de-
tectable by routine immunologic-based assays
used to quantitate urinary albumin excretion.
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Fig. 2. Working model of albuminuria, particularly for albumin excre-
tion in humans<2 g/day. Decreased lysosomal activity can lead to de-
creased albumin fragmentation and increased immunoreactive albumin
excretion. This apparent albuminuria can occur without any changes in
glomerular permeability.
affecting this balance and increasing the relative amounts
of intact immunoreactive material; hence, yielding an ap-
parent ‘albuminuria.’ In reality, they are merely altering
the balance in lysosomal degradation of filtered albumin,
yielding more immunoreactive albumin without changing
the total amount of albumin excreted.
CONCLUSION
The conclusions from this study have important ram-
ifications for any type of albuminuria <2 g/day in hu-
mans. These states may include cardiovascular disease,
diabetic kidney disease, preeclampsia, hypertension, ex-
ercise, and orthstatic albuminuria. Albuminuria in these
states may be the result of factors affecting the degrada-
tion pathway of filtered albumin, rather than a primary
effect on glomerular permeability. This mechanism does
not eliminate other observations in these disease states,
such as changes in glomerular tissue morphology, possi-
ble role of endothelial cells, and hyperfiltration. However,
rather than affecting permeability, per se, they are proba-
bly involved, or have been affected by increases in TGF-b
levels or other cytokines that effect post-glomerular base-
ment membrane albumin uptake and processing.
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